# Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

> **NCT00729053** · PHASE2 · COMPLETED · sponsor: **Idera Pharmaceuticals, Inc.** · enrollment: 92 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** IMO-2055

## Key facts

- **NCT ID:** NCT00729053
- **Lead sponsor:** Idera Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2008-04
- **Final completion:** 2008-11
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2018-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729053, "Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*